About Sêmeia
Sêmeia is a company founded in 2017 by Daniel Szeftel and Pierre Hornus. It operates as a SaaS (Software-as-a-Service) and HealthTech. Sêmeia has raised $8.39 million across 1 funding round from investors including Banque des Territoires, Orange Ventures and Malakoff Humanis. Sêmeia offers products and services including NephroWise, MentalWise, OncoWise, CardioWise, and PneumoWise. Sêmeia operates in a competitive market with competitors including Vivify Health, Somatix, PhysIQ, Flashback Technologies and Doctomatic, among others.
- Founders Daniel Szeftel, Pierre Hornus
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$8.39 M (USD)
in 1 rounds
-
Latest Funding Round
$8.39 M (USD), Series A
Dec 08, 2022
-
Investors
Banque des Territoires
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sêmeia
Sêmeia offers a comprehensive portfolio of products and services, including NephroWise, MentalWise, OncoWise, CardioWise, and PneumoWise.
Patient monitoring for kidney transplant and insufficiency cases.
Mental health tracking for bipolar and depression patients.
Oncology patient follow-up for breast and prostate cancer.
Cardiac care monitoring for heart failure and diabetes.
Respiratory monitoring for asthma and sleep apnea patients.
Rheumatology tracking for patients with rheumatoid arthritis issues.
Funding Insights of Sêmeia
Sêmeia has successfully raised a total of $8.39M through 1 strategic funding round. The most recent funding activity was a Series A round of $8.39 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sêmeia
Sêmeia has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Banque des Territoires, Orange Ventures and Malakoff Humanis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are directed toward startups and early-stage companies.
|
Locked | Locked | Locked | |
|
Offers insurance, savings, and retirement services for individuals, enterprises, and independents.
|
Locked | Locked | Locked | |
|
Legal and finance advisory services are provided to clients.
|
Locked | Locked | Locked |
Investor details for Sêmeia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sêmeia
Investment portfolio details for Sêmeia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sêmeia
Detailed financials for Sêmeia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sêmeia Comparisons
Peer comparison for Sêmeia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sêmeia
Sêmeia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Vivify Health, Somatix, PhysIQ, Flashback Technologies and Doctomatic, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cloud-based platform for remote patient monitoring and engagement is delivered.
|
|
| Locked | Locked | Locked |
AI-based remote health monitoring tools are provided for patient care.
|
|
| Locked | Locked | Locked |
Personalized physiology data analytics are delivered via an AI platform.
|
|
| Locked | Locked | Locked |
AI-based decision support is provided for professionals in critical care.
|
|
| Locked | Locked | Locked |
AI-based healthcare monitoring is provided for providers and patients.
|
Detailed competitors of Sêmeia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sêmeia
Complete news archive for Sêmeia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sêmeia
Sêmeia was founded in 2017 and raised its 1st funding round 5 years after it was founded.
Pierre Hornus is the current CEO of Sêmeia. They have also founded this company.
Sêmeia is a funded company, having raised a total of $8.39M across 1 funding round to date.
Sêmeia is engaged in providing telemonitoring solutions for patients with chronic conditions. Various sectors such as nephrology, oncology, mental health, cardiology, pneumology, and rheumatology are covered by their specialized products. Data security and AI-driven risk prediction are integrated to enhance personalized care plans. Patient data is managed securely with direct communication tools like chat and teleconsultation. The solutions are designed to improve care quality and reduce hospitalizations by enabling timely medical interventions.
Sêmeia's top competitors include Vivify Health, Somatix and PhysIQ.
Sêmeia offers NephroWise, MentalWise, OncoWise, CardioWise, and 2 more products and services.
Sêmeia has 3 investors. Key investors include Banque des Territoires, Orange Ventures, and Malakoff Humanis.